The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Human Rabies Immunoglobulin (IM) Market Research Report 2025
Synopsis
Rabies immunoglobulin (RIG) is a medication made up of antibodies against the rabies virus. It is used to prevent rabies following exposure.
Figure Human Rabies Immunoglobulin (IM) is rabies immunoglobulin antibody by the high price of healthy human plasma protein low temperature ethanol separation or other separation methods approved separation and purification, and by virus removal and inactivation treatment is made. Mainly used for rabies or other crazy animal bites, scratches patient's passive immunization.
In this report, we study ERIG (Equine Rabies Immunoglobulin) and HRIG (Human Rabies Immunoglobulin)
The global Human Rabies Immunoglobulin (IM) market was valued at US$ 396 million in 2023 and is anticipated to reach US$ 606.3 million by 2030, witnessing a CAGR of 6.2% during the forecast period 2024-2030.
Global Human Rabies Immunoglobulin (IM) key players include CSL Behring, Grifols, Sanofi, etc. Global top three manufacturers hold a share about 60%.
North America is the largest market, with a share over 30%, followed by China and Europe, both have a share about 45 percent.
In terms of product, HRIG is the largest segment, with a share over 85%. And in terms of application, the largest application is Category III Exposure, followed by Category II Exposure.
This report aims to provide a comprehensive presentation of the global market for Human Rabies Immunoglobulin (IM), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Human Rabies Immunoglobulin (IM).
Report Scope
The Human Rabies Immunoglobulin (IM) market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Human Rabies Immunoglobulin (IM) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Human Rabies Immunoglobulin (IM) manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
CSL Behring
Grifols
Sanofi
Sichuan Yuanda Shuyang
CNBG
Kamada
CBPO
Shuanglin Bio
Weiguang Bio
Shanghai RAAS
Bharat Serum
VINS
Segment by Type
ERIG
HRIG
Segment by Application
Category II Exposure
Category III Exposure
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Human Rabies Immunoglobulin (IM) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Human Rabies Immunoglobulin (IM) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Rabies immunoglobulin (RIG) is a medication made up of antibodies against the rabies virus. It is used to prevent rabies following exposure.
Figure Human Rabies Immunoglobulin (IM) is rabies immunoglobulin antibody by the high price of healthy human plasma protein low temperature ethanol separation or other separation methods approved separation and purification, and by virus removal and inactivation treatment is made. Mainly used for rabies or other crazy animal bites, scratches patient's passive immunization.
In this report, we study ERIG (Equine Rabies Immunoglobulin) and HRIG (Human Rabies Immunoglobulin)
The global Human Rabies Immunoglobulin (IM) market was valued at US$ 396 million in 2023 and is anticipated to reach US$ 606.3 million by 2030, witnessing a CAGR of 6.2% during the forecast period 2024-2030.
Global Human Rabies Immunoglobulin (IM) key players include CSL Behring, Grifols, Sanofi, etc. Global top three manufacturers hold a share about 60%.
North America is the largest market, with a share over 30%, followed by China and Europe, both have a share about 45 percent.
In terms of product, HRIG is the largest segment, with a share over 85%. And in terms of application, the largest application is Category III Exposure, followed by Category II Exposure.
This report aims to provide a comprehensive presentation of the global market for Human Rabies Immunoglobulin (IM), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Human Rabies Immunoglobulin (IM).
Report Scope
The Human Rabies Immunoglobulin (IM) market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Human Rabies Immunoglobulin (IM) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Human Rabies Immunoglobulin (IM) manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
CSL Behring
Grifols
Sanofi
Sichuan Yuanda Shuyang
CNBG
Kamada
CBPO
Shuanglin Bio
Weiguang Bio
Shanghai RAAS
Bharat Serum
VINS
Segment by Type
ERIG
HRIG
Segment by Application
Category II Exposure
Category III Exposure
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Human Rabies Immunoglobulin (IM) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Human Rabies Immunoglobulin (IM) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Human Rabies Immunoglobulin (IM) Market Overview
1.1 Product Overview and Scope of Human Rabies Immunoglobulin (IM)
1.2 Human Rabies Immunoglobulin (IM) Segment by Type
1.2.1 Global Human Rabies Immunoglobulin (IM) Market Value Comparison by Type (2024-2030)
1.2.2 ERIG
1.2.3 HRIG
1.3 Human Rabies Immunoglobulin (IM) Segment by Application
1.3.1 Global Human Rabies Immunoglobulin (IM) Market Value by Application: (2024-2030)
1.3.2 Category II Exposure
1.3.3 Category III Exposure
1.4 Global Human Rabies Immunoglobulin (IM) Market Size Estimates and Forecasts
1.4.1 Global Human Rabies Immunoglobulin (IM) Revenue 2019-2030
1.4.2 Global Human Rabies Immunoglobulin (IM) Sales 2019-2030
1.4.3 Global Human Rabies Immunoglobulin (IM) Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Human Rabies Immunoglobulin (IM) Market Competition by Manufacturers
2.1 Global Human Rabies Immunoglobulin (IM) Sales Market Share by Manufacturers (2019-2024)
2.2 Global Human Rabies Immunoglobulin (IM) Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Human Rabies Immunoglobulin (IM) Average Price by Manufacturers (2019-2024)
2.4 Global Human Rabies Immunoglobulin (IM) Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Human Rabies Immunoglobulin (IM), Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Human Rabies Immunoglobulin (IM), Product Type & Application
2.7 Human Rabies Immunoglobulin (IM) Market Competitive Situation and Trends
2.7.1 Human Rabies Immunoglobulin (IM) Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Human Rabies Immunoglobulin (IM) Players Market Share by Revenue
2.7.3 Global Human Rabies Immunoglobulin (IM) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Human Rabies Immunoglobulin (IM) Retrospective Market Scenario by Region
3.1 Global Human Rabies Immunoglobulin (IM) Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Human Rabies Immunoglobulin (IM) Global Human Rabies Immunoglobulin (IM) Sales by Region: 2019-2030
3.2.1 Global Human Rabies Immunoglobulin (IM) Sales by Region: 2019-2024
3.2.2 Global Human Rabies Immunoglobulin (IM) Sales by Region: 2025-2030
3.3 Global Human Rabies Immunoglobulin (IM) Global Human Rabies Immunoglobulin (IM) Revenue by Region: 2019-2030
3.3.1 Global Human Rabies Immunoglobulin (IM) Revenue by Region: 2019-2024
3.3.2 Global Human Rabies Immunoglobulin (IM) Revenue by Region: 2025-2030
3.4 North America Human Rabies Immunoglobulin (IM) Market Facts & Figures by Country
3.4.1 North America Human Rabies Immunoglobulin (IM) Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Human Rabies Immunoglobulin (IM) Sales by Country (2019-2030)
3.4.3 North America Human Rabies Immunoglobulin (IM) Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Human Rabies Immunoglobulin (IM) Market Facts & Figures by Country
3.5.1 Europe Human Rabies Immunoglobulin (IM) Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Human Rabies Immunoglobulin (IM) Sales by Country (2019-2030)
3.5.3 Europe Human Rabies Immunoglobulin (IM) Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Human Rabies Immunoglobulin (IM) Market Facts & Figures by Country
3.6.1 Asia Pacific Human Rabies Immunoglobulin (IM) Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Human Rabies Immunoglobulin (IM) Sales by Country (2019-2030)
3.6.3 Asia Pacific Human Rabies Immunoglobulin (IM) Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Human Rabies Immunoglobulin (IM) Market Facts & Figures by Country
3.7.1 Latin America Human Rabies Immunoglobulin (IM) Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Human Rabies Immunoglobulin (IM) Sales by Country (2019-2030)
3.7.3 Latin America Human Rabies Immunoglobulin (IM) Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Human Rabies Immunoglobulin (IM) Market Facts & Figures by Country
3.8.1 Middle East and Africa Human Rabies Immunoglobulin (IM) Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Human Rabies Immunoglobulin (IM) Sales by Country (2019-2030)
3.8.3 Middle East and Africa Human Rabies Immunoglobulin (IM) Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Human Rabies Immunoglobulin (IM) Sales by Type (2019-2030)
4.1.1 Global Human Rabies Immunoglobulin (IM) Sales by Type (2019-2024)
4.1.2 Global Human Rabies Immunoglobulin (IM) Sales by Type (2025-2030)
4.1.3 Global Human Rabies Immunoglobulin (IM) Sales Market Share by Type (2019-2030)
4.2 Global Human Rabies Immunoglobulin (IM) Revenue by Type (2019-2030)
4.2.1 Global Human Rabies Immunoglobulin (IM) Revenue by Type (2019-2024)
4.2.2 Global Human Rabies Immunoglobulin (IM) Revenue by Type (2025-2030)
4.2.3 Global Human Rabies Immunoglobulin (IM) Revenue Market Share by Type (2019-2030)
4.3 Global Human Rabies Immunoglobulin (IM) Price by Type (2019-2030)
5 Segment by Application
5.1 Global Human Rabies Immunoglobulin (IM) Sales by Application (2019-2030)
5.1.1 Global Human Rabies Immunoglobulin (IM) Sales by Application (2019-2024)
5.1.2 Global Human Rabies Immunoglobulin (IM) Sales by Application (2025-2030)
5.1.3 Global Human Rabies Immunoglobulin (IM) Sales Market Share by Application (2019-2030)
5.2 Global Human Rabies Immunoglobulin (IM) Revenue by Application (2019-2030)
5.2.1 Global Human Rabies Immunoglobulin (IM) Revenue by Application (2019-2024)
5.2.2 Global Human Rabies Immunoglobulin (IM) Revenue by Application (2025-2030)
5.2.3 Global Human Rabies Immunoglobulin (IM) Revenue Market Share by Application (2019-2030)
5.3 Global Human Rabies Immunoglobulin (IM) Price by Application (2019-2030)
6 Key Companies Profiled
6.1 CSL Behring
6.1.1 CSL Behring Corporation Information
6.1.2 CSL Behring Description and Business Overview
6.1.3 CSL Behring Human Rabies Immunoglobulin (IM) Sales, Revenue and Gross Margin (2019-2024)
6.1.4 CSL Behring Human Rabies Immunoglobulin (IM) Product Portfolio
6.1.5 CSL Behring Recent Developments/Updates
6.2 Grifols
6.2.1 Grifols Corporation Information
6.2.2 Grifols Description and Business Overview
6.2.3 Grifols Human Rabies Immunoglobulin (IM) Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Grifols Human Rabies Immunoglobulin (IM) Product Portfolio
6.2.5 Grifols Recent Developments/Updates
6.3 Sanofi
6.3.1 Sanofi Corporation Information
6.3.2 Sanofi Description and Business Overview
6.3.3 Sanofi Human Rabies Immunoglobulin (IM) Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Sanofi Human Rabies Immunoglobulin (IM) Product Portfolio
6.3.5 Sanofi Recent Developments/Updates
6.4 Sichuan Yuanda Shuyang
6.4.1 Sichuan Yuanda Shuyang Corporation Information
6.4.2 Sichuan Yuanda Shuyang Description and Business Overview
6.4.3 Sichuan Yuanda Shuyang Human Rabies Immunoglobulin (IM) Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Sichuan Yuanda Shuyang Human Rabies Immunoglobulin (IM) Product Portfolio
6.4.5 Sichuan Yuanda Shuyang Recent Developments/Updates
6.5 CNBG
6.5.1 CNBG Corporation Information
6.5.2 CNBG Description and Business Overview
6.5.3 CNBG Human Rabies Immunoglobulin (IM) Sales, Revenue and Gross Margin (2019-2024)
6.5.4 CNBG Human Rabies Immunoglobulin (IM) Product Portfolio
6.5.5 CNBG Recent Developments/Updates
6.6 Kamada
6.6.1 Kamada Corporation Information
6.6.2 Kamada Description and Business Overview
6.6.3 Kamada Human Rabies Immunoglobulin (IM) Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Kamada Human Rabies Immunoglobulin (IM) Product Portfolio
6.6.5 Kamada Recent Developments/Updates
6.7 CBPO
6.6.1 CBPO Corporation Information
6.6.2 CBPO Description and Business Overview
6.6.3 CBPO Human Rabies Immunoglobulin (IM) Sales, Revenue and Gross Margin (2019-2024)
6.4.4 CBPO Human Rabies Immunoglobulin (IM) Product Portfolio
6.7.5 CBPO Recent Developments/Updates
6.8 Shuanglin Bio
6.8.1 Shuanglin Bio Corporation Information
6.8.2 Shuanglin Bio Description and Business Overview
6.8.3 Shuanglin Bio Human Rabies Immunoglobulin (IM) Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Shuanglin Bio Human Rabies Immunoglobulin (IM) Product Portfolio
6.8.5 Shuanglin Bio Recent Developments/Updates
6.9 Weiguang Bio
6.9.1 Weiguang Bio Corporation Information
6.9.2 Weiguang Bio Description and Business Overview
6.9.3 Weiguang Bio Human Rabies Immunoglobulin (IM) Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Weiguang Bio Human Rabies Immunoglobulin (IM) Product Portfolio
6.9.5 Weiguang Bio Recent Developments/Updates
6.10 Shanghai RAAS
6.10.1 Shanghai RAAS Corporation Information
6.10.2 Shanghai RAAS Description and Business Overview
6.10.3 Shanghai RAAS Human Rabies Immunoglobulin (IM) Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Shanghai RAAS Human Rabies Immunoglobulin (IM) Product Portfolio
6.10.5 Shanghai RAAS Recent Developments/Updates
6.11 Bharat Serum
6.11.1 Bharat Serum Corporation Information
6.11.2 Bharat Serum Human Rabies Immunoglobulin (IM) Description and Business Overview
6.11.3 Bharat Serum Human Rabies Immunoglobulin (IM) Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Bharat Serum Human Rabies Immunoglobulin (IM) Product Portfolio
6.11.5 Bharat Serum Recent Developments/Updates
6.12 VINS
6.12.1 VINS Corporation Information
6.12.2 VINS Human Rabies Immunoglobulin (IM) Description and Business Overview
6.12.3 VINS Human Rabies Immunoglobulin (IM) Sales, Revenue and Gross Margin (2019-2024)
6.12.4 VINS Human Rabies Immunoglobulin (IM) Product Portfolio
6.12.5 VINS Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Human Rabies Immunoglobulin (IM) Industry Chain Analysis
7.2 Human Rabies Immunoglobulin (IM) Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Human Rabies Immunoglobulin (IM) Production Mode & Process
7.4 Human Rabies Immunoglobulin (IM) Sales and Marketing
7.4.1 Human Rabies Immunoglobulin (IM) Sales Channels
7.4.2 Human Rabies Immunoglobulin (IM) Distributors
7.5 Human Rabies Immunoglobulin (IM) Customers
8 Human Rabies Immunoglobulin (IM) Market Dynamics
8.1 Human Rabies Immunoglobulin (IM) Industry Trends
8.2 Human Rabies Immunoglobulin (IM) Market Drivers
8.3 Human Rabies Immunoglobulin (IM) Market Challenges
8.4 Human Rabies Immunoglobulin (IM) Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
